A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
15/03/2021at 15:44

Novo Nordisk has three biopharma blockbusters on the way

The EVP of Novo Nordisk's biopharma business sees blockbuster potential in its three most advanced drug candidates, according to Danish media.
Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Following a time period in which Novo Nordisk's biopharma business has had some growth issues, there's light at the end of the tunnel in the view of Novo Nordisk Biopharm's Executive Vice President Ludovic Helfgott, according to Danish newspaper Finans.

He explains that Biopharm's currently most advanced drug candidates – growth hormone somapacitan and hemophilia drugs Mim8 and Concizumab – are all potential blockbusters in his view. By that, he means that they can potentially sell for more than USD 1bn.

"We're delivering incredibly strong growth in the diabetes area, and I am convinced that we can deliver the same growth with our Biopharm products," Helfgott tells Finans.

In 2020, Novo Nordisk's whole biopharma area had a DKK 18.9bn (USD 3.0bn) revenue after going up 1 percent in local currency.

Novo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember" 

Related articles:

  • Photo: PR / Novo Nordisk

    Novo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Application Manager

See all jobs

Jobs

  • Lead Data Architect

  • Commercial Director

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Principal Laboratory Technologist

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge